ASND News

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Ascend Learning Acquires TAMS to Strengthen Faculty Operations at Nursing Schools

ATI Engage® Series Honored with Gold Stevie® Award for Technology Breakthrough of the Year in Educational Technology

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

V2 Communications to Host Webinar on CEO Visibility as a Business Imperative

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism